Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Immune Therapeutics, Inc. (IMUN)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsDec-31-21Dec-31-20Dec-31-19Dec-31-18Dec-31-17Dec-31-16Dec-31-15Dec-31-14
   10-K10-K10-K10-K/A10-K10-K10-K10-K/A
Revenues  0.00.00.00.10.00.00.00.0
            Revenue growth    -100.0% -100.0%-78.6%  
Cost of goods sold  0.00.00.00.00.02.94.30.0
Gross profit  0.00.00.00.10.0-2.9-4.30.0
            Gross margin  0.0%  58.0% -83944.2%-26625.7% 
Selling, general and administrative  0.60.82.43.22.83.92.74.1
Research and development  0.20.10.30.10.40.41.02.4
Equity in earnings     -0.4    
Other operating expenses  -4.5 0.10.82.77.02.026.0
EBITDA   [+] -0.9-2.8-4.5-5.9-14.3-10.0-32.5
            EBITDA margin  1898476.5%  -3928.9% -412080.0%-61627.2% 
Depreciation   0.00.00.00.00.00.0 
EBITA  3.8-0.9-2.8-4.5-5.9-14.3-10.0-32.5
            EBITA margin  1898476.5%  -3930.4% -412125.0%-61642.9% 
Amortization of intangibles        0.62.9
EBIT   [+]3.8-0.9-2.8-4.5-5.9-14.3-10.6-35.4
            EBIT margin  1898476.5%  -3930.4% -412125.0%-65299.4% 
Non-recurring items   [+]4.5     5.29.9
Interest expense  0.20.50.91.21.23.40.30.4
Other income (expense), net   [+]4.53.00.3-3.0-0.8-2.1-0.9-4.3
Pre-tax income  3.61.6-3.4-8.6-7.9-19.8-16.9-49.9
Income taxes  0.00.00.00.00.00.00.00.0
            Tax rate  0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Minority interest     -0.5-0.6-0.3-2.7-1.7
Net income  3.61.6-3.4-8.6-7.3-19.5-14.2-48.3
            Net margin  1793017.0%  -7599.7% -563713.6%-87933.0% 
   
Basic EPS   [+]$7.43$3.44($7.59)($20.08)($0.02)($0.09)($0.09)($0.49)
Diluted EPS   [+]$0.38$0.10($7.59)($20.08)($0.02)($0.09)($0.09)($0.49)
   
Shares outstanding (basic)   [+]0.50.50.40.4320.7216.7153.298.5
Shares outstanding (diluted)   [+]9.416.00.40.4320.7216.7153.298.5
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy